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Background: Given the unpredictable timing of deceased donor organs and the need for blood transfusion, this
study was carried out to determine the rate and risk factors for transfusion in order to identifying a low-risk cohort
in the face of a critical blood shortage.
Methods: This retrospective chart review examined 306 consecutive deceased solitary kidney transplant recipients
from January 2006 to August 2012.
Results: Records show that 80 (26.1%) patients were transfused with a total of 300 units (0.98 units/transplant)
during their first hospital stay. Transfusions were higher in patients on warfarin (8/14, 57%, 5.1 units/transplant) and
antiplatelet agents (46/136, 33.8%, 1.1 unit/transplant) compared to no anticoagulants (74/156, 16.7%, 0.47 units/
transplant). In a multivariable logistic regression analysis warfarin (odd ratio (OR) 8.2, 95% confidence interval (CI)
2.5–27, P=0.001), antiplatelet agents (OR 2.9, 95% CI 1.6–5.3, P=0.001), recipient age ≥55 years (OR 2.2, 95% CI
1.2–3.9, P=0.008), recipient male (OR 0.36, 95% CI 0.2–0.64, P=0.001) and preop hemoglobin ≥115 g/L (OR 0.32, 95%
CI 0.18–0.57, P<0.001) were independent predictors of blood transfusion. Lower bleeding cohorts with transfusion
rates <5% could not be identified.
Conclusion: The need for blood is significantly higher in subjects on either warfarin or antiplatelet agents. These
patients might be avoided if kidney transplantation is to occur during a critical blood shortage. Unfortunately even
patients not on anticoagulation are at some risk.
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The need for blood transfusion after kidney transplant-
ation is not well studied. Rates in one study approached
50% in those receiving deceased donor organs, a rate
that seems quite high [1]. The need for blood transfu-
sion with respect to anticoagulation has been addressed
in two studies [2,3]. One reported that patients receiving
anticoagulation were not at increased risk of bleeding
[2], the second concluded the use of warfarin preopera-
tively was not associated with adverse outcomes in a
small case–control series [3]. These observations seem
counter to the experience at our center. Lastly the
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reproduction in any medium, provided the ora shortage [4]. The document specifically addressed
transplantation and requested that centers collect
current rates of blood transfusion in order to categorize
high- and low-risk procedures and groups. Knowing
risks would aid in individualizing informed consent. The
document recommended delaying live donation proce-
dures but allowed deceased donation surgery with in-
formed consent.
The purpose of this study was to examine the preva-
lence of blood transfusion in deceased organ donor soli-
tary kidney transplantation at our center, to identify risk
factors for transfusion need in particular anticoagulation
status, and to examine the level of hemoglobin that trig-
gered transfusion. Ideally a low-risk cohort could be
identified that could be transplanted in the face of a crit-
ical blood shortage to avoid organ waste.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Consecutive deceased donor organ transplant recipients
of solitary kidneys were identified in the Program’s elec-
tronic database from January 2006 until November 2012.
Combined organ and living donor transplants procedures
were excluded. Data were extracted from our electronic
health records which came into existence in January
2006. Approval for this retrospective study was obtained
from our institution’s research ethics board.
All patients received induction with either basiliximab
or antithymocyte globulin (ATG) and all received pre-
operative solumedrol (500 mg) intravenously. ATG was
reserved for those who were repeat transplant recipients,
deceased cardiac donor recipients, and the highly sensi-
tized. Postoperative patients received oral tacrolimus,
mycophenolate, and prednisone. All patients were treated
with sulfamethoxazole-trimethoprim for pneumocystis
prophylaxis and oral rantidine for gastrointestinal ulcer
prophylaxis. Patients on a proton pump inhibitor pre
transplant were continued on this agent in place of raniti-
dine. All patients were to receive subcutaneous heparin
5000 units twice or thrice daily for venous thromboembol-
ism prophylaxis. Patients on warfarin received vitamin K
and fresh frozen plasma to reduce their INR to <1.5. How-
ever two patients received a prothrombin complex to re-
duce their INR. No therapy was given to patients on
antiplatelet agents.
Data extracted included packed red cells transfused,
hemoglobin at transfusion, anticoagulation on admission
(warfarin, antiplatelet use, or both), erythropoiesis stimu-
lating agents, cause of ESRD, diabetes mellitus, age, gen-
der, delayed graft function (DGF as defined as need for
dialysis post transplantation), days in hospital, cold ische-
mic time, CMV status, HLA sensitization as defined by
most recent panel reactive antibody (PRA,%), reversal of
anticoagulation therapy (in the case of warfarin treated pa-
tients, postoperative prophylaxis). Patient data for transfu-
sions were limited to the first hospitalization or to 30 days
whichever came first.
Variables associated with transfusion need were exam-
ined by binary logistic regression analysis. Variables sta-
tistically associated with transfusion in a univariable
analysis were studied in a multivariable model. For age
and pre-transplantation hemoglobin receiver-operator
characteristic curves were used to identify values with
the best sensitivity and specificity. Significance was as-
sumed at 5%. Inappropriate transfusion was defined as
initiation of therapy for hemoglobin >90 g/L. Statistical
analysis was performed using IBM SPSS Statistics soft-
ware version 20.0.
Results
There were 306 patients in the cohort. Blood transfusion
occurred in 80 (26.1%) patients for a total of 300 units(0.98 units/transplant). Characteristics associated with
the need for blood are shown in Table 1. Transfusion
rates (Table 2) were higher in patients on warfarin (8/14,
57%, 5.1 units/transplant) and antiplatelet agents (46/
136, 33.8%, 1.14 units/transplant) compared to those not
on anticoagulants (26/156, 16.7%, 0.47 units/transplant).
Overall transfused patients received 3.8±3.8 units.
Slightly more than half (44/80) of patients transfused re-
ceived either 1 (n=14) or 2 (n=30) units. Only 18 (5.9%)
patients received ≥5 units and six received ≥10 units. Of
the 18 patients requiring 5 or more units 15 were either
on antiplatelet agents or warfarin. Therefore only three
(1.9%) patients on no anticoagulants, nine (6.6%) on
antiplatelet agents, and four (29%) on warfarin required
had a large transfusion requirement (≥5 units). Of the
patients on antiplatelet agents almost all were on aspirin
and only four were on clopidigrel.
Age ≥55 years and hemoglobin ≥115 g/L were deter-
mined to have the best sensitivity and specificity to predict
the need for a blood transfusion. In a multivariable logistic
regression analysis warfarin (OR 8.2, 95% CI 2.5–27,
P=0.001), antiplatelet agents (OR 2.9, 95% CI 1.6–
5.3, P=0.001), recipient age ≥55 (OR 2.2, 95% CI 1.2–3.9,
P=0.008), recipient male (OR 0.36, 95% CI 0.2–0.64,
P=0.001) and pre op hemoglobin ≥115 g/L (OR 0.32, 95%
CI 0.18–0.57, P <0.001) were independent predictors of
blood transfusion. Most patients received venous throm-
boembolism prophylaxis (281 or 92% of the cohort) and
this treatment was not associated with bleeding (OR 0.92,
95% CI 0.34–2.4, P=0.87). Diabetes mellitus was signifi-
cant in a univariable analysis but not in the multivaria-
ble analysis.
The mean hemoglobin at transfusion was 68±8 g/L. Only
9 units were transfused for a hemoglobin ≥90 g/L and 21
for a hemoglobin level between 80 and 89 g/L. There-
fore 90% of transfused units were for a hemoglobin le-
vel <80 g/L. Transfusion decisions were not consistent as
60 patients had nadir hemoglobin levels <80 g/L and were
not transfused.
Lower bleeding cohorts could be identified however
the reduction in blood use was minimal. For example,
those on no anticoagulants and male sex reduced the co-
hort to 83 patients (27%) with a transfusion rate of 10.8%
(0.37 units/transplant). Those on no anticoagulants and a
hemoglobin ≥115 g/L reduced the cohort to 31% of the
overall population sample with a transfusion rate of
12.5% (0.36 units/transplant). Restricting those on no an-
ticoagulants and recipient age <55 years reduced the co-
hort to 36% of the sample with a transfusion rate of
13.6%. Men, no anticoagulants and hemoglobin >114 g/L
represented only 51 patients (16.7% of the cohort) with a
transfusion rate of 9.8% (0.26 units/transplant). The low-
est transfusion cohort consisted of men <55 years of age,
no anticoagulants and hemoglobin ≥115 g/L. These
Table 1 Patient characteristics stratified by blood transfusion
No transfusion (n=226) Transfusion (n=80) Probability
Age (years) 50 ± 13 55 ± 12 0.002
Male gender (%) 149 (66) 37 (50) 0.008
Diabetes mellitus (%) 45 (20) 27 (34) 0.012
HLA MM 4.1 ± 1.3 4.2 ± 1.4 0.451
cPRA (%) 14 ± 27 20 ± 32 0.634
Hb pre g/L 121 ± 14 114 ± 13 <0.001
Platelet count 230 ± 73 230 ± 88 0.980
Donor age (years) 47 ± 7 50 ± 16 0.137
Donor sex male (%) 91 (40) 45 (56) 0.014
CIT (h) 12.5 ± 6.3 11.8 ± 5.3 0.403
Antiplatelet (%) 90 (40) 46 (58) 0.006
Warfarin (%) 6 (3) 8 (10) 0.007
Hb nadir g/L 88 ± 13 69 ± 10 <0.001
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and 7.5% were transfused.
Discussion
Based on this analysis patients on anticoagulants espe-
cially warfarin are at particularly increased risk of requir-
ing blood transfusion post kidney transplantation. This
analysis shows that transfusion is also not uncommon
(16.7%) in those not on anticoagulants. Smaller cohorts
could be identified but this greatly restricted access
without greatly reducing the need for blood.Table 2 Patient cohort by anticoagulation status
All patients (n=306) Warfarin (n=14) A
Age (years) 51 ± 13 50 ± 10 5
Male gender 186 (61) 10 (71) 9
Diabetes mellitus (%) 72 (24) 1 (7.1) 5
cPRA (%) 16 ± 28 14 ± 29 1
HLA MM 4.1 ± 1.4 3.4 ± 1.6 4
CIT (h) 13.1 ± 10.8 12.4 ± 6.1 1
Donor age (years) 48 ± 17 52 ± 17 5
Donor gender male 136 (44) 6 (43) 6
Hb pre g/L 119 ± 14 122 ± 14 1
INR 1.03 ± 0.22 1.89 ± 0.36 0
Platelet count 230 ± 77 230 ± 94 2
Transfusion (%) 80 (26) 8 (57) 4
Units total (units/patient) 300 (0.98) 71 (5.1) 1
Hb nadir g/L 83 ± 15 77 ± 23 8
Length of hospital stay (days) 12.5 ± 10.2 18.7 ± 13.7 1This analysis was restricted to deceased donors since
live donation could be delayed during a blood shortage.
Transfusion was also higher in male donors (OR 1.9,
P=0.014) however this was not included in the analysis
since most would want to proceed with the transplant-
ation regardless to avoid organ waste. Donor age was
not significantly associated with transfusion. There may
be other factors that correlate to transfusion including
the presence of heart disease. Unfortunately this was not
specifically examined. Those who were on antiplatelet
agents were almost certain to have vascular disease orntiplatelet agents (n=136) No anticoagulant (n=156) Probability
5 ± 11 48 ± 13 <0.001
3 (68) 83 (53) 0.021
6 (41) 15 (9.6) <0.001
4 ± 26 18 ± 30 0.484
.2 ± 1.2 4.2 ± 1.2 0.082
4.2 ± 14.4 11.8 ± 6.2 0.084
1 ± 15 45 ± 17 0.006
2 (46) 68 (44) 0.936
19 ± 14 119 ± 14 0.658
.99 ± 0.10 0.98 ± 0.08 <0.001
33 ± 85 227 ± 70 0.828
6 (33.8) 26 (16.7) <0.001
55 (1.14) 74 (0.47) <0.001
1 ± 14 85 ± 14 0.018
3.9 ± 12.9 10.6 ± 5.9 0.001
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were more likely to be transfused and this might have
been due to a perceived higher risk of vascular disease.
Patients at high risk of cardiovascular events might also
be avoided during a critical blood shortage but this was
not specifically examined.
The frequency of blood transfusion was greater than ap-
preciated but in keeping with other studies. In a single
center from the US, Scornik et al. found rates of transfu-
sion to be 51% of deceased donor kidney recipients and
30% of live donor recipients [1]. In our study 26% of de-
ceased donors and 14% of 209 live donor kidney recipients
over the same time period (data not shown) were trans-
fused. In another single center US study, 25% of kidney re-
cipients were transfused. A UK study reported 45% of
patients on warfarin and 29% of non-warfarin-treated pa-
tients required blood [3]. In aggregate our transfusion
rates appear to the same or lower than these reports.
The impact of anticoagulation of transfusion rates was
analyzed in two of the above studies. The UK study as
noted above reported that those on warfarin were at no
increased risk (45% versus 29%) [3]. However it is not
clear if the controls included subjects on antiplatelet
agents and given the small sample size a significant dif-
ference may have been missed. In the larger study by
Eng et al. pre transplant anticoagulation was not associ-
ated with the need for transfusion. However patients re-
ceiving postoperative heparin required more blood.
Their study may have included live and deceased donor
recipients [2]. Analyzing both live and deceased donors
may have reduced the likelihood of detecting an effect of
anticoagulation on transfusion rates in deceased donors.
In an analysis of our live donors anticoagulation with
antiplatelet agents or warfarin was also not associated with
bleeding (data not shown). More of our patients were on
antiplatelet agents (136 of 306) compared to the Eng study
(69 of 327). In the Eng study those on antiplatelet agents
who were transfused tended to receive on average more
units (3.5 units for clopidogrel, 3.3 units for ASA, and 2.5
units for no anticoagulation). Differences between centers
may well be an important determinant of transfusion prac-
tice and rates.
It is not clear how appropriate our transfusion practice
approached the ideal. A recent meta-analysis of blood
transfusion practice did not find any adverse effects of a
restrictive policy of blood transfusion compared to a lib-
eral policy [5]. Unfortunately none of the 19 studies
were of kidney transplant recipients but did include a
variety of subjects with acute bleeding in the context of
surgery. Adverse effects, including 30-day mortality,
stroke, myocardial infarction, and length of stay, showed
a trend to be less in the restricted arm. For the most
part our practice approached the restrictive spectrum
(mean hemoglobin at transfusion was 68 g/L) however10% were transfused at more liberal rates (hemoglo-
bin >90 g/L). A more restrictive policy may have re-
duced the need of transfusion in our center without
compromising outcomes. The effects of blood transfu-
sion on new HLA antibody formation appears to be low
in the short term [1]. However the cumulative effect of
transfusions may compromise outcomes in those need-
ing a repeat transplant [6].
Conclusions
Given the above, restricting access to deceased kidney
transplantation to those not on anticoagulants might be
prudent during a critical blood shortage. Patients under-
going transplantation during a blood shortage should be
informed of their risk. At our center the risk is small
(2%) for a large bleed but modest (16.7%) for the prob-
ability of needing some blood for those not on anticoag-
ulants. The rates are considerably higher for those on
antiplatelet agents and warfarin. Each center should re-
view their transfusion practice and know their transfu-
sion rates to better inform their patients.
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